Dec 1, 2021
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma A...
297
Dec 22, 2016
NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Solid tumors
NCT02663518: Phase 1: A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors NCT02663518: Phase 1: A...
39